- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Financially Fit Penny Stocks
U.S. Pharmaceuticals & Biotech Financially Fit Penny Stocks
Results
217
A Penny Stocks screener, typically smaller or younger companies trading at a price below 5, with a focus on solid financial health that should present companies with a lower risk profile than other early-stage businesses
217 companies
Kiora Pharmaceuticals
Market Cap: US$8.0m
A clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases in the United States.
KPRX
US$2.66
7D
1.3%
1Y
-48.6%
Puma Biotechnology
Market Cap: US$139.9m
A biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
PBYI
US$2.82
7D
-2.8%
1Y
-46.5%
Cabaletta Bio
Market Cap: US$62.4m
A clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.
CABA
US$1.23
7D
10.8%
1Y
-92.8%
Citius Pharmaceuticals
Market Cap: US$8.1m
A biopharmaceutical company, focuses on the development and commercialization of critical care products.
CTXR
US$0.94
7D
-7.4%
1Y
-95.2%
CureVac
Market Cap: US$715.6m
A biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
CVAC
US$3.19
7D
23.2%
1Y
9.6%
Protalix BioTherapeutics
Market Cap: US$188.1m
A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
PLX
US$2.41
7D
0.8%
1Y
104.2%
Vanda Pharmaceuticals
Market Cap: US$240.8m
A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
VNDA
US$4.13
7D
-0.2%
1Y
0.2%
Evoke Pharma
Market Cap: US$4.6m
Operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases.
EVOK
US$2.20
7D
-2.2%
1Y
-64.1%
aTyr Pharma
Market Cap: US$263.9m
A biotherapeutics company, engages in the discovery and development of medicines based on novel functions of tRNA synthetases in the United States.
ATYR
US$2.97
7D
13.4%
1Y
70.7%
InflaRx
Market Cap: US$62.5m
A clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States.
IFRX
US$0.92
7D
-8.5%
1Y
-38.4%
Organogenesis Holdings
Market Cap: US$540.3m
A regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States.
ORGO
US$4.26
7D
10.1%
1Y
47.9%
Xenetic Biosciences
Market Cap: US$3.5m
A biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers.
XBIO
US$2.30
7D
-6.7%
1Y
-46.9%
Acrivon Therapeutics
Market Cap: US$50.8m
A clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform.
ACRV
US$1.62
7D
7.3%
1Y
-83.8%
Allogene Therapeutics
Market Cap: US$315.0m
A clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.
ALLO
US$1.45
7D
0.7%
1Y
-61.8%
RenovoRx
Market Cap: US$28.2m
A clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment.
RNXT
US$0.77
7D
-12.4%
1Y
-36.7%
Nutriband
Market Cap: US$52.4m
Develops a portfolio of transdermal pharmaceutical products.
NTRB
US$4.72
7D
-12.6%
1Y
7.0%
Silence Therapeutics
Market Cap: US$121.4m
A biotechnology company, engages in the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.
SLN
US$2.57
7D
-1.5%
1Y
-88.4%
Aldeyra Therapeutics
Market Cap: US$114.0m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases.
ALDX
US$1.91
7D
1.1%
1Y
-55.1%
ImmunoPrecise Antibodies
Market Cap: US$19.7m
A techbio company, engages in the development of therapeutic antibodies.
IPA
US$0.43
7D
19.8%
1Y
-68.3%
Grace Therapeutics
Market Cap: US$27.2m
Engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
GRCE
US$1.98
7D
-1.0%
1Y
-41.9%
Quantum-Si
Market Cap: US$228.9m
A life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS).
QSI
US$1.25
7D
10.6%
1Y
-26.0%
Biofrontera
Market Cap: US$7.5m
A biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
BFRI
US$0.84
7D
13.5%
1Y
-59.8%
Precigen
Market Cap: US$411.7m
A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
PGEN
US$1.40
7D
12.9%
1Y
-1.4%
Alpha Cognition
Market Cap: US$70.1m
A clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).
ACOG
US$4.38
7D
-9.4%
1Y
-65.1%
Adverum Biotechnologies
Market Cap: US$71.4m
A clinical-stage company, develops gene therapy product candidates to treat ocular diseases.
ADVM
US$3.43
7D
-11.1%
1Y
-70.8%
ESSA Pharma
Market Cap: US$70.1m
A clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer.
EPIX
US$1.58
7D
6.8%
1Y
-79.6%
Unicycive Therapeutics
Market Cap: US$65.6m
A biotechnology company, develops treatments for various medical conditions in the United States.
UNCY
US$0.55
7D
6.1%
1Y
-55.1%
Werewolf Therapeutics
Market Cap: US$31.8m
A biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer.
HOWL
US$0.71
7D
1.7%
1Y
-84.9%
Vor Biopharma
Market Cap: US$87.4m
Operates as a clinical-stage cell and genome engineering company.
VOR
US$0.70
7D
23.4%
1Y
-63.2%
Cardiff Oncology
Market Cap: US$164.3m
A clinical-stage biotechnology company, develops novel therapies to treat various cancers in California.
CRDF
US$2.47
7D
-10.2%
1Y
-56.0%
Enlivex Therapeutics
Market Cap: US$21.2m
Operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel.
ENLV
US$0.90
7D
1.1%
1Y
-43.2%
PharmaCyte Biotech
Market Cap: US$8.5m
A biotechnology company, develops and commercializes cellular therapies for cancer in the United States.
PMCB
US$1.23
7D
-0.8%
1Y
-44.8%
Protara Therapeutics
Market Cap: US$143.8m
A clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases.
TARA
US$3.91
7D
0.3%
1Y
30.3%
4D Molecular Therapeutics
Market Cap: US$121.8m
A late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.
FDMT
US$2.63
7D
-5.1%
1Y
-90.0%
Cassava Sciences
Market Cap: US$61.4m
A clinical stage biotechnology company, develops drugs for neurodegenerative diseases.
SAVA
US$1.27
7D
-2.3%
1Y
-94.4%
Vincerx Pharma
Market Cap: US$1.4m
A clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States.
VINC
US$0.27
7D
-56.2%
1Y
-98.6%